SecBot SecBot
6-K ·Filed Nov 9, 2026

ARGX

ARGENX SE
NEUTRAL
Impact 5/10
Horizonweeks Processed7d 16h ago SEC0001104659-26-124060
Notable filing: 6-K
Actionable Insight • Neutral

The acquisition is a platform-expanding deal that adds peptide discovery to argenx's antibody toolkit, but the $550M upfront cash outlay will reduce cash reserves. Watch for closing conditions and any future updates on milestone achievement timelines that could affect total consideration.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$962.27
T+0 close · Nov 9, 2026 · via day close
Latest settled
−1.18%
T+5 · $950.95
Vs SPY
+0.52%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $962.27entry
  2. T+1 · 7d ago +0.96%α +1.33% · $971.55
  3. T+5 · 16h ago −1.18%α +0.52% · $950.95
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

argenx announced a definitive agreement to acquire Unnatural Products, Inc. (UNP) for up to $1.15 billion, including $550 million upfront in cash and up to $595 million in contingent milestone payments. The deal adds a macrocyclic peptide discovery platform to argenx's antibody engineering capabilities, with potential for oral and long-acting immunology medicines. The acquisition is expected to close by year-end.

Key Facts

  • Upfront cash payment of $550 million from cash on hand
  • Up to $595 million in development and regulatory milestone payments
  • Total potential consideration up to approximately $1.15 billion
  • UNP will continue operating from Santa Cruz, California with its current team
  • argenx already held a minority stake in UNP prior to the acquisition
  • Transaction approved by both boards; expected to close by end of 2026
  • Morgan Stanley served as financial advisor to argenx; DLA Piper as legal advisor

Financial Impact

$550M upfront cash plus up to $595M in milestones; total up to $1.15B

cashr&d pipelineplatform capabilities

Risk Factors

  • Integration risk: combining peptide and antibody platforms may not yield expected synergies
  • Milestone payments are contingent on development and regulatory success, which is uncertain
  • Cash outlay of $550M reduces financial flexibility for other investments or operations

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (26 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-124060
Document: tm2629301d2_6k.htm0001104659-26-124060
Document: 0001104659-26-124060-index-headers.html0001104659-26-124060
Document: 0001104659-26-124060-index.html0001104659-26-124060
Document: 0001104659-26-124060.txt0001104659-26-124060
Earnings Context (Synthetic; results releases only)0001104659-26-124060

Track record

23 reports on ARGX

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +30.22% at T+60 after the Jun 3, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  2. Nov 9, 20267d ago 6-K Neutral 5/10 Viewing Entry $962.27 Now $950.95 −1.18% settles Dec 8
  3. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
  4. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $950.95 +6.28% settles Dec 4
  5. Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $950.95 +5.91% settles Nov 27
  6. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $950.95 +8.59% settles Nov 19
  7. Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $950.95 +15.18% ▲ +15.18% +18.64% vs SPY
  8. Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $950.95 +16.16% ▲ +13.77% +19.06% vs SPY
  9. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $950.95 −2.03% ▼ −10.21% −10.87% vs SPY
  10. Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $950.95 −3.36% ▼ −16.81% −18.93% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens Wed (10h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026